We conclude that in patients with moderate-to-severe psoriasis, circulating levels of IL-17C and PI3 may serve as biomarkers of effective systemic anti-psoriatic treatment and that concurrent CVD is linked with modulation of the relationship between IL-17 pathway proteins and psoriasis disease activity. This evidence concerns the gene IL17A and psoriasis.